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Abstract
Multidrug-resistant Gram-negative bacteria (MDR-GNB) are an emerging public health threat. Accurate estimates of their clinical impact
are vital for justifying interventions directed towards preventing or managing infections caused by these pathogens. A retrospective
observational cohort study was conducted between 1 January 2007 and 31 July 2009, involving subjects with healthcare-associated and
nosocomial Gram-negative bacteraemia at two large Singaporean hospitals. Outcomes studied were mortality and length of stay post-
onset of bacteraemia in survivors (LOS). There were 675 subjects (301 with MDR-GNB) matching study inclusion criteria. On multivar-
iate analysis, multidrug resistance was not associated with 30-day mortality, but it was independently associated with longer LOS in sur-
vivors (coefﬁcient, 0.34; 95% CI, 0.21–0.48; p < 0.001). The excess LOS attributable to multidrug resistance after adjustment for
confounders was 6.1 days. Other independent risk factors for higher mortality included male gender, higher APACHE II score, higher
Charlson comorbidity index, intensive care unit stay and presence of concomitant pneumonia. Concomitant urinary tract infection and
admission to a surgical discipline were associated with lower risk of mortality. Appropriate empirical antibiotic therapy was neither
associated with 30-day mortality nor LOS, although the study was not powered to assess this covariate adequately. Our study adds to
existing evidence that multidrug resistance per se is not associated with higher mortality when effective antibiotics are used for deﬁnitive
therapy. However, its association with longer hospitalization justiﬁes the use of control efforts.
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Introduction
Antibiotic-resistant Gram-negative bacteria are a major public
health threat, increasing in prevalence globally in both com-
munity and institutional settings [1]. The Antimicrobial Avail-
ability Task Force formed by the Infectious Diseases Society
of America (IDSA) had identiﬁed three Gram-negative patho-
gens of particular importance, namely, extended-spectrum
b-lactamase (ESBL)-producing Enterobacteriaceae, Acinetobac-
ter baumannii and Pseudomonas aeruginosa [1]. These organ-
isms are also major pathogens in Singaporean hospitals,
where the prevalence of antibiotic resistance is high [2].
The perceived hazards of Gram-negative antimicrobial
resistance stem from two interlinked concerns: diminishing
therapeutic options for the treatment of infections caused by
these bacteria [1], and the potentially greater negative impact
on both clinical outcomes and healthcare costs [3–7].
Although the majority of published studies demonstrate an
independent association between Gram-negative resistance
and worse clinical outcomes [4–9], these results are not uni-
versal and may be confounded by the impact of delayed
appropriate antimicrobial therapy, differing study designs and
deﬁnitions of resistance, and potential biases in the selection
of study subjects [3,10,11].
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Nonetheless, accurate estimates of the impact of Gram-
negative antimicrobial resistance are crucial for justifying
interventions aimed at preventing or managing these infec-
tions, and for evaluating their effectiveness [12]. The primary
objective of our study was to evaluate clinical outcomes
associated with healthcare-associated Gram-negative bactera-
emia, and to assess the independent effect of multidrug resis-
tance on these outcomes.
Patients and Methods
Study design and setting
We conducted a dual-centre retrospective, observational
cohort study at the two largest public sector hospitals in Sin-
gapore—the 1600-bed Singapore General Hospital and the
1400-bed Tan Tock Seng Hospital. The recruitment period
was between 1 January 2007 and 31 July 2009, while the fol-
low-up period was up to the point of discharge/death of the
ﬁnal subject.
Participants
Subjects were consecutive inpatients with healthcare-associ-
ated Gram-negative bacteraemia and sepsis due to Entero-
bacteriaceae, Pseudomonas aeruginosa and/or Acinetobacter
baumannii. Only the ﬁrst episode of bacteraemia was
recorded for each subject. Subjects were identiﬁed from
each hospital’s microbiology laboratory database, and
screened for eligibility by conformation with sepsis criteria at
the time of bacteraemia by trained researchers [13]. Subjects
with mixed Gram-positive and Gram-negative bacteraemia
were excluded from the study.
We considered bacteraemia to be healthcare-associated if
it fulﬁlled previously published criteria for nosocomial or
healthcare-associated bacteraemia [14].
Data sources and variables
Demographical, clinical and microbiological variables as well
as outcomes were collected from inpatient clinical, adminis-
trative and laboratory records.
Multidrug resistance was deﬁned as resistance to all anti-
microbial agents tested in three or more antibiotic classes
[15]. This deﬁnition would encompass the majority of deﬁni-
tions of multidrug resistance in the published literature
[16,17]. Antibiotic susceptibility testing—including screening
for extended-spectrum beta-lactamase (ESBL) produc-
tion—was performed using the Kirby–Bauer disk-diffusion
method following Clinical Laboratory Standards Institute
(CLSI) guidelines [18]. The antibiotic classes and antibiotics
tested included b-lactam/b-lactamase inhibitors (amoxicillin/
clavulanate, piperacillin/tazobactam and ampicillin/sulbactam),
cephalosporins (ceftazidime and cefepime), ﬂuoroquinolones
(ciproﬂoxacin), aminoglycosides (gentamicin and amikacin),
carbapenems (imipenem and meropenem), and polymyxins.
Subjects with mixed multidrug-resistant (MDR) and non-
MDR Gram-negative bacteraemia were classiﬁed as having
MDR bacteraemia.
Severity of illness was scored using the Acute Physiology
and Chronic Health Evaluation, version II (APACHE II), with
variables taken at the day of positive cultures [19], while the
Charlson [20] co-morbidity index was used as an aggregate
measure for prognosticating subjects’ co-morbidities. Inten-
sive care unit (ICU) stay prior to bacteraemia was also
recorded as a potential indicator of severity of illness. Other
concomitant sites of infection were classiﬁed according to
the National Healthcare Safety Network deﬁnitions [21].
We considered antibiotic therapy to be ‘appropriate’ if
prescribed antibiotics had in vitro activity against all isolated
organisms and appropriate doses were prescribed based on
the Sanford Guide to Antimicrobial Therapy [22]. ‘Empirical
antibiotic therapy’ was deﬁned as antibiotics received within
the ﬁrst 24 h following blood cultures [23], whereas ‘deﬁni-
tive antibiotic therapy’ was deﬁned as antibiotics received
after 48 h post-blood cultures (i.e. when the organism had
been identiﬁed and susceptibility proﬁles were available). For
subjects who died within 72 h of blood cultures, deﬁnitive
antibiotic therapy was not used as a variable for determining
association with all outcomes.
The primary outcome was 30-day mortality, while the sec-
ondary outcome was length of hospitalization post-onset of
bacteraemia (LOS) in survivors.
Bias and quantitative variables
Selection bias was minimized by inclusion of all subjects
matching inclusion criteria during the study period. The dis-
tributions of quantitative variables were assessed and non-
parametric analyses were selected for skewed distributions.
For regression models, the data were transformed to the
natural logarithmic scale to ensure normality.
Study size
For determination of the cohort size, we used the results of
Schwaber and Carmeli’s meta-analysis (pooled crude relative
risk of 1.85 with regards to mortality and pooled crude mor-
tality of 20% among non-ESBL patients) as the best compro-
mise in view of the heterogeneity of existing studies [24]. We
estimated that at least 267 hospital admissions with MDR
bacteraemia, with a similar number of non-MDR bacteraemia,
would be required to detect similar differences in mortality
with a statistical power of 80% and a 5% signiﬁcance level.
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Statistical methods
Intercooled Stata 10.2 (StataCorp, College Station, TX, USA)
was used for all statistical calculations, and level of signiﬁ-
cance set at 5%.
For determination of covariates associated with 30-day
mortality, we performed logistic regression, with a multivari-
ate model based on signiﬁcant covariates identiﬁed in the
univariate analysis using the likelihood ratio test, with proba-
bility of removal set at 0.05. For LOS, we used the ordinary
least squares linear regression model to examine both uni-
variate and multivariate factors associated with this outcome.
Data were analysed on a natural logarithmic scale as explor-
atory analyses revealed that the residuals from the models
were not normally distributed. To calculate excess LOS
between MDR and non-MDR cases after adjustment for
confounders, we used the following formula: (e0.34 · 14.8) –
14.8, where 0.34 is the adjusted coefﬁcient from the
multivariate model, and 14.8 days is the baseline LOS for the
non-MDR group.
Comparative analyses were performed between non-MDR
and MDR groups as well as between survivors and 30-day
fatalities. Dichotomous variables were analyzed with the v2
test or Fisher’s exact test appropriately, and continuous vari-
ables were analysed with the Mann–Whitney U-test.
Ethics
The study was approved by the ethics review boards of both
institutions (reference: E/08/193).
Role of the funding source
This study was funded by a Tier 1 grant from the Ministry of
Education Academic Research Fund. The study sponsor had
no role in the design, implementation, analysis or write-up of
the study.
Results
During the study period, there were 675 subjects with
healthcare-associated Gram-negative bacteraemia included in
the study cohort. Recruitment rates were similar for both
hospitals. The Gram-negative bacteria isolated were Escheri-
chia coli (197 cases), Klebsiella pneumoniae (162 cases), P. aeru-
ginosa (135 cases), A. baumannii (76 cases), Enterobacter spp.
(58 cases) and Proteus mirabilis (47 cases).
There were 301 subjects with MDR bacteraemia, with the
demographical and clinical variables shown in Table 1. No
pan-resistant bacteria were cultured. Subjects with MDR bac-
teraemia were more likely to be male, have been hospital-
ized for a longer duration prior to bacteraemia or lodged in
the ICU, and were more acutely ill by APACHE II criteria.
They were less likely to have been bacteraemic within 2 days
of hospitalization or to have received either appropriate
empirical and/or deﬁnitive antibiotic therapy. There was a
lower proportion of urinary tract infections (UTIs) associ-
ated with MDR bacteraemia. A. baumannii and Enterobacter
spp. strains causing healthcare-associated bacteraemia were
more likely to be MDR.
Two hundred and seventy-seven (92.6%) bacteria labeled
MDR were resistant to either ceftazidime (Enterobacteria-
ceae) or the carbapenems (P. aeruginosa and A. baumannii)
while only nine (2.4%) non-MDR bacteria were resistant as
described above (p < 0.001). Inappropriate deﬁnitive anti-
biotic therapy was prescribed to 25 (3.7%) subjects.
The 30-day mortality for healthcare-associated Gram-neg-
ative bacteraemia was 22.2% (150 subjects), with 73 (19.4%)
TABLE 1. Descriptive characteristics of hospitalized
patients with healthcare-associated Gram-negative bactera-
emia, segregated by multidrug resistance
Characteristic
Non-MDR
bacteraemia
(n = 374)
MDR
bacteraemia
(n = 301) p-value
Hospital (%)
Singapore General Hospital 175 (46.5) 127 (42.2) 0.243
Tan Tock Seng Hospital 199 (53.2) 174 (57.8)
Median age, years (IQR) 67 (56–77) 67 (53–77) 0.273
Male gender (%) 182 (48.7) 172 (57.1) 0.030
Ethnicity (%)
Chinese 295 (79.9) 221 (73.7) 0.223
Malay 40 (10.7) 37 (12.3)
Indian 34 (9.1) 32 (10.7)
Discipline (%)
Medical 263 (70.3) 203 (67.7) 0.502
Surgical 111 (29.7) 97 (32.3)
Bacteraemia within 48 h of
hospitalization (%)
192 (51.3) 94 (31.2) <0.001
Median length of stay prior to
bacteraemia, days (IQR)
2 (0–10) 8 (1–18) <0.001
Median APACHE II score (IQR) 9 (5–13) 12 (8–17) <0.001
Median Charlson index (IQR) 8 (5–10) 8 (5–10) 0.946
ICU stay prior to bacteraemia (%) 24 (6.4) 45 (15.0) <0.001
Organism (%)
A. baumannii 31 (8.2) 45 (14.3) <0.001
Enterobacter spp. 0 (0.0) 58 (19.3)
Escherichia coli 130 (34.8) 67 (22.3)
Klebsiella pneumoniae 81 (21.7) 81 (26.9)
Proteus mirabilis 35 (9.4) 13 (4.3)
P. aeruginosa 97 (25.9) 39 (13.0)
Polymicrobial bacteraemia (%) 74 (19.8) 59 (19.7) 1.000
Other sites of infection (%) [17]
Bone and joint infection 2 (0.5) 6 (2.0) 0.148
Catheter related 34 (9.1) 40 (13.3) 0.085
Intra-abdominal infection 44 (11.7) 33 (11.0) 0.808
Pneumonia 64 (17.1) 56 (18.6) 0.614
Skin and soft tissue infection 34 (9.1) 41 (13.6) 0.066
Urinary tract infection 133 (35.6) 81 (26.9) 0.020
Appropriate antibiotic therapy (%)
Empirical 297 (79.4) 84 (27.9) <0.001
Deﬁnitive 348 (98.3)a 256 (93.4)a 0.003
MDR, multidrug-resistant; IQR, interquartile range; ICU, intensive care unit.
aForty subjects had died within 72 h of bacteraemia and were therefore not
included in the denominator for deﬁnitive antibiotic therapy. These included 18
non-MDR and 22 MDR bacteraemia cases.
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and 77 (25.8%) deaths among subjects with non-MDR and
MDR bacteraemia, respectively (p 0.049). Demographical and
clinical variables for survivors and case fatalities are displayed
in Table 2. Forty deaths had occurred within 72 h from the
time of blood cultures and were excluded from analyses
involving deﬁnitive antibiotic therapy. Median LOS was
16 days (interquartile range (IQR), 10–31 days): 13 days
(IQR, 8–24 days) and 20 days (IQR, 13–42 days) for subjects
with non-MDR and MDR bacteraemia, respectively
(p < 0.001).
Among subjects with MDR bacteraemia, 58 (26.7%) had
received inappropriate empirical therapy and died within
30 days, while 19 (22.6%) that had received appropriate
therapy died (p 0.464). For those with non-MDR bactera-
emia, 19 (24.7%) had received inappropriate empirical ther-
apy and died, compared with 54 (18.2%) of those who
received appropriate therapy (p 0.200).
The results of univariate analysis for association of subject
characteristics with outcomes are shown in Tables 2 and 3,
while signiﬁcant covariates found in the ﬁnal multivariable
models are displayed in Table 4. On multivariate analysis,
ICU stay prior to development of bacteraemia was strongly
correlated with higher 30-day mortality. Other factors
included male gender, higher APACHE II score, higher Charl-
son index, and presence of concomitant pneumonia. Being a
surgical inpatient was protective, as was having concomitant
UTI. Forcing in appropriate empirical antibiotic therapy as a
covariate showed that this had no statistically signiﬁcant
impact on 30-day mortality in this cohort (Table 4). Forcing
in MDR status as a covariate in the ﬁnal model of a second-
ary multivariate analysis similarly conﬁrmed its lack of statis-
tically signiﬁcant impact (OR, 1.05; 95% CI, 0.64–1.72; p
0.835). Appropriate deﬁnitive antibiotic therapy was not
included in the initial multivariate analysis on mortality as this
TABLE 2. Descriptive characteristics of hospitalized patients with healthcare-associated Gram-negative bacteraemia segre-
gated by 30-day mortality, with univariate analysis of the impact of cohort characteristics on mortality
Characteristic
Survivors
(n = 525)
Fatalities
(n = 150) p-value
30-day mortality
Odds ratio 95% CI p-value
Hospital (%)
Singapore General Hospital 257 (49.0) 45 (30.0) <0.001 NA NA NA
Tan Tock Seng Hospital 268 (51.0) 105 (70.0)
Median age, years (IQR) 67 (54–77) 71 (57–79) 0.007 1.02 1.01–1.02 0.003
Male gender (%) 261 (49.7) 93 (62.0) 0.009 1.65 1.14–2.39 0.008
Ethnicity (%)
Chinese 394 (75.0) 122 (81.3) 0.350 1.00 – –
Malay 61 (11.6) 16 (10.7) 0.85 0.47–1.52 0.579
Indian 56 (10.7) 10 (6.7) 0.58 0.29–1.16 0.125
Discipline (%)
Medical 342 (65.1) 124 (82.7) <0.001 1.00 – –
Surgical 183 (34.9) 26 (17.3) 0.39 0.25–0.62 <0.001
Bacteraemia within 48 h of hospitalization (%) 231 (44.0) 55 (36.7) 0.112 NA NA NA
Median length of stay prior to bacteraemia, days (IQR) 4 (0–13) 6 (1–17) 0.067 1.00 0.99–1.01 0.650
Median APACHE II score (IQR) 9 (5–13) 14 (9–21) <0.001 1.13 1.09–1.16 <0.001
Median Charlson index (IQR) 7 (5–10) 9 (7–11) <0.001 1.17 1.11–1.24 <0.001
ICU stay prior to bacteraemia (%) 24 (4.6) 45 (30.0) <0.001 8.95 5.22–15.32 <0.001
Organism (%)
A. baumannii 48 (9.1) 26 (17.3) <0.001 1.000 – –
Enterobacter spp. 49 (9.3) 9 (6.0) 0.34 0.14–0.80 0.013
Escherichia coli 177 (33.7) 20 (13.3) 0.21 0.11–0.41 <0.001
Klebsiella pneumoniae 117 (22.3) 45 (30.0) 0.71 0.39–1.28 0.254
Proteus mirabilis 35 (6.7) 13 (8.7) 0.69 0.31–1.52 0.353
P. aeruginosa 99 (18.9) 37 (24.7) 0.69 0.38–1.27 0.232
Polymicrobial bacteraemia (%) 91 (17.4) 42 (28.0) 0.005 1.61 1.16–2.26 0.005
MDR bacteraemia 224 (42.7) 77 (51.3) 0.063 1.42 0.99–2.04 0.060
Other sites of infection (%) [17]
Bone and joint infection 6 (1.1) 2 (1.3) 1.000 NA NA NA
Catheter related 62 (11.8) 12 (8.0) 0.236 0.65 0.34–1.24 0.191
Intra-abdominal infection 67 (12.8) 10 (6.7) 0.038 0.49 0.24–0.97 0.042
Pneumonia 64 (12.2) 56 (37.3) <0.001 4.29 2.81–6.54 <0.001
Skin and soft tissue infection 60 (11.4) 15 (10.0) 0.768 0.86 0.47–1.56 0.624
Urinary tract infection 188 (35.8) 26 (17.3) <0.001 0.37 0.23–0.58 <0.001
Appropriate antibiotic therapy (%)
Empirical 308 (58.7) 73 (48.7) 0.032 0.67 0.46–0.96 0.030
Deﬁnitive 511 (97.7) 93 (88.6)a <0.001 0.18 0.08–0.42 <0.001
MDR, multidrug-resistant; IQR, interquartile range; ICU, intensive care unit; NA, not assessed.
aForty subjects had died within 72 h of bacteraemia and were therefore not included in the denominator for deﬁnitive antibiotic therapy. These included 18 non-MDR and
22 MDR bacteraemia cases.
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would exclude the subset of subjects that had died within
72 h of bacteraemia. However, a subsequent multivariate
analysis incorporating this variable showed that it was
protective for subjects surviving beyond the initial 72 h (OR,
0.13; 95% CI, 0.05–0.37, p < 0.001).
MDR bacteraemia, ICU stay prior to development of bac-
teraemia, male gender and higher APACHE II score were
independently associated with longer LOS, while concomitant
intra-abdominal infection or urinary tract infection were
associated with shorter LOS in survivors. After adjustment
for confounders, the excess LOS in subjects with healthcare-
associated MDR Gram-negative bacteraemia was 6.1 days.
Subgroup analysis excluding the subset of patients with
polymicrobial Gram-negative bacteraemia did not yield signif-
icantly different results (not shown).
Discussion
The heterogeneity of published studies with respect to study
design, deﬁnitions, subjects and outcomes measured has led
to some confusion with regards to the actual impact of
antibiotic resistance on mortality from Gram-negative infec-
tions [3–11,23,24]. In general, although MDR bacteria may
develop compensatory mutations that overcome the ﬁtness
costs of antimicrobial resistance [25], they are not more vir-
ulent than their antibiotic-susceptible counterparts. There-
fore delay in initiating appropriate antibiotics, which is
signiﬁcantly associated with antibiotic-resistant Gram-nega-
tive infections in many studies, was thought to be an impor-
tant contributory factor towards mortality in such infections
in the majority of published studies [5–9,24].
In our study, however, neither multidrug resistance nor
inappropriate empirical therapy was found to be indepen-
dently associated with mortality. The former ﬁnding is not
an effect of small sample size, as our cohort is adequately
powered [24]. However, it is underpowered to assess the
association between empirical antibiotic therapy and mor-
tality. Initial physiological reserves of patients are likely to
be important for surviving Gram-negative bacteraemia, and
indeed surrogate markers denoting lack of these reserves
were associated with greater 30-day mortality in our
study. Because only a relatively small proportion of
TABLE 3. Univariate analysis of the impact of cohort char-
acteristics on length of stay post-onset of bacteraemia
(LOS) in survivors
Characteristic
LOS
Coefﬁcienta 95% CI p-value
Age )0.01 )0.01 to 0.00 0.015
Male gender 0.17 0.02 to 0.32 0.031
Ethnicity
Chinese (reference) 0.00 – 0.00
Malay )0.03 )0.27 to 0.21 0.803
Indian )0.17 )0.41 to 0.08 0.185
Surgical discipline )0.07 )0.23 to 0.09 0.365
APACHE II score 0.04 0.03 to 0.06 <0.001
Charlson comorbidity index )0.02 )0.04 to 0.00 0.022
ICU stay 0.95 0.60 to 1.30 <0.001
Polymicrobial bacteraemia 0.03 )0.17 to 0.23 0.797
Organism type
Acinetobacter baumannii (reference) 0.000 – –
Enterobacter spp. )0.21 )0.56 to 0.13 0.227
Escherichia coli )0.48 )0.76 to )0.21 0.001
Klebsiella pneumoniae )0.09 )0.39 to 0.20 0.528
Proteus mirabilis )0.29 )0.67 to 0.08 0.128
Pseudomonas aeruginosa )0.28 )0.58 to 0.02 0.064
MDR bacteraemia 0.45 0.30 to 0.59 <0.001
Other sites of infection [17]
Catheter related 0.20 )0.03 to 0.43 0.090
Intra-abdominal infection )0.31 )0.53 to )0.08 0.007
Pneumonia 0.07 )0.16 to 0.30 0.567
Skin and soft tissue infection 0.24 0.01 to 0.48 0.045
Urinary tract infection )0.27 )0.43 to )0.12 0.001
Appropriate antibiotic therapy
Empirical )0.20 )0.35 to )0.05 0.011
Deﬁnitive 0.42 )0.08 to 0.91 0.100
MDR, multidrug-resistant; ICU, intensive care unit.
aThe regression coefﬁcient represents the expected change in the predicted
value of LOS for each unit change in the analysed covariate, with negative
results representing an inverse relationship.
TABLE 4. Signiﬁcant covariates on multivariable analysis
with 30-day mortality and length of stay post-onset of bac-
teraemia (LOS) as outcomes
Characteristic
30-day mortalitya
Odds ratio 95% CI p-value
Male gender 1.75 1.11 to 2.77 0.016
Surgical discipline 0.27 0.14 to 0.54 <0.001
Higher Charlson comorbidity index 1.24 1.15 to 1.33 <0.001
Higher APACHE II score 1.07 1.04 to 1.11 <0.001
Pneumonia (other site of infection) 1.86 1.08 to 3.22 0.025
Urinary tract infection (other
site of infection)
0.44 0.25 to 0.77 0.005
Intensive care unit stay 10.98 5.02 to 24.00 <0.001
Appropriate empirical antibiotic
therapyb
0.87 0.55 to 1.38 0.544
Characteristic
Length of stay post-onset of
bacteraemiac
Coefﬁcientd 95% CI p-value
Male gender 0.15 0.01 to 0.28 0.032
Higher APACHE II score 0.03 0.02 to 0.05 <0.001
Other sites of infection [17]
Intra-abdominal infection )0.30 )0.51 to )0.09 0.005
Urinary tract infection )0.22 )0.36 to )0.07 0.004
MDR bacteraemia 0.34 0.21 to 0.48 <0.001
Intensive care unit stay 0.58 0.25 to 0.91 0.001
MDR, multidrug-resistant.
aFor the multivariable logistic regression analysis with 30-day mortality as out-
come, the number of subjects included in the ﬁnal equation was 675, Hosmer-
Lemeshow goodness of ﬁt test p-value = 0.630, and prediction of the model
(area under the ROC curve) = 0.859.
bAppropriate empirical antibiotic therapy variable was forced into the model.
cFor the multivariable linear regression analysis with length of stay post-onset of
bacteraemia as outcome, the number of subjects included in the ﬁnal equation
was 525, and the model results were signiﬁcant with p < 0.001.
dThe regression coefﬁcient represents the expected change in the predicted
value of LOS for each unit change in the analysed covariate, with negative
results representing an inverse relationship.
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subjects had high APACHE II scores or were in the ICU
prior to bacteraemia, whereas most other studies were
mainly or partly ICU based [5–9], it is plausible that the
better physiological reserves of our subjects negated any
potential impact of inappropriate antibiotic therapy. These
results corroborate other studies demonstrating that anti-
biotic resistance [3,11] and delayed appropriate therapy
[10] may have limited impact on mortality outcomes in
severe Gram-negative infections outside of certain popula-
tion subsets [9,23]. Appropriate deﬁnitive therapy, how-
ever, appears to be integral for surviving such infections
after the ﬁrst 72 h.
That surgical inpatients had lower mortality is harder to
explain, save perhaps that it may indicate underlying health
states (the surgical subjects were generally younger and had
fewer co-morbidities) that were not elicited using more con-
ventional measures. Our ﬁndings corroborate recent studies
suggesting that male gender is an independent risk factor for
mortality [26,27].
In accordance with other studies, we found that multidrug
resistance was independently associated with LOS in survi-
vors [4,5,7]. Patients admitted to the ICU or who have
higher APACHE II scores may naturally require a longer
recovery time in the hospital. It is less clear why male gen-
der and intra-abdominal infections were associated with a
shorter LOS, unlike urinary tract infections, which are con-
sidered low-risk sources of infection and therefore corre-
lated with quicker recovery [3]. Perhaps the more severe
illness associated with male gender may have been translated
into longer LOS in our study.
This study has several limitations. Firstly, a heteroge-
neous mix of Gram-negative bacteria were included and
analysed collectively; infections by these bacteria may
potentially have different risk factors and prognoses. Sec-
ondly, we studied the impact of Gram-negative bacteraemia
only in terms of LOS. Other relevant outcomes such as
ﬁnancial costs or health-related quality of life were not
evaluated, and these are equally important in understanding
the full impact of such infections in terms of patient, hos-
pital and societal perspectives. Thirdly, our deﬁnitions for
empirical and deﬁnitive antibiotic therapy leave out the
period between 24 and 48 h post-cultures. This period is
hard to deﬁne as a signiﬁcant number of cases had under-
gone switching of antibiotics due to preliminary reports of
Gram-negative bacteraemia by the laboratory. We feel that
a separate study may be necessary to ascertain the impact
of antibiotics prescribed during this period, as this is
beyond the scope of the current work. Fourthly, individual
risk factors and chronic conditions such as neutropenia,
hypotension, hypoalbuminemia, renal impairment, transplan-
tation and mechanical ventilation, among others, may have
profound independent associations that may not be well
captured by aggregate indices [22], but these were not
individually analysed in our study. Lastly, the mechanisms
of resistance to antibiotics, particularly the beta-lactams,
were not elucidated from the MDR organisms. However,
the association between different mechanisms of resistance
and outcomes of infection remains unclear at this point in
time.
The more recent deﬁnition of healthcare-associated bac-
teraemia excludes those cases where infection is present on
hospital admission [21]. Nonetheless, the broader deﬁnitions
proposed by Friedman et al. [14] retain merit in identifying
patients where there is a higher risk of bacteraemia caused
by potentially antibiotic-resistant bacteria, permitting rational
use of broad-spectrum antibiotics.
In conclusion, our study supports previous ﬁndings that
multidrug resistance by itself is not associated with higher
mortality even for a serious infection such as bacteraemia, as
long as effective antibiotics remain for deﬁnitive therapy.
However, it is associated with longer hospitalization in survi-
vors, thereby justifying current efforts directed at their con-
trol. More work is required to elucidate the possible global
impact of multidrug-resistant Gram-negative bacteraemia,
from both patient and societal perspectives.
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